Showing 3531-3540 of 4075 results for "".
- Survey Highlights Room for Improvement in AK Awarenesshttps://practicaldermatology.com/news/survey-highlights-room-for-improvement-in-ak-awareness/2461746/As many as 85% of people are unaware of actinic keratosis (AK), according to a new survey from Almirall. The survey of more than 2,500 participants over the age or 35 aimed to understand the level of knowledge about AK and skin health habits within the general population of Spain, Germa
- Epigenetic Mechanisms Activated by GHK-Cu Increase Skin Collagen Densityhttps://practicaldermatology.com/news/epigenetic-mechanisms-activated-by-ghk-cu-increase-skin-collagen-density/2461744/Epigenetic mechanisms activated by GHK-Cu may increase skin collagen density, new research suggests. The naturally occurring peptide GHK-Cu (GHK from glycyl-L-histidyl-L-lysine bound to a copper ion), which affects
- AAD Survey: Too Few Folks Use Sun Protection During Outdoor Activitieshttps://practicaldermatology.com/news/aad-survey-too-few-folks-use-sun-protection-during-outdoor-activities/2461735/Although 90% of Americans report protecting themselves from the sun when going to beaches or pools, far fewer plan for it before other outdoor activities, according to a recent American Academy of Dermatology (AAD) survey of more than 1,000 U.S. adults. "The head, neck, arms, and l
- AI In Action: Machine Learning Algorithms May Aid Diagnosis and Treatment of ADhttps://practicaldermatology.com/news/ai-in-action-machine-learning-algorithms-may-aid-diagnosis-and-treatment-of-ad/2461726/Researchers have developed six relatively stable and reliable diagnosis and efficacy evaluation prediction models for atopic dermatitis (AD) based on a machine learning algorithm. Songjiang Wu, a PhD candidate in dermatology from Third Xiangya Hospital at the Central South University in
- More Phase 3 Data: Dermavant’s VTAMA Hits Primary and Secondary Endpoints for Kids and Adults with ADhttps://practicaldermatology.com/news/phase-3-data-dermavants-vtama-hits-primary-and-secondary-endpoints-for-kids-and-adults-with-ad/2461720/Dermavant Sciences’ VTAMA performed well in in adults and kids with atopic dermatitis, according to topline results from ADORING 1, the company’s second atopic dermatitis (AD) Phase 3 trial. VTAMA is a novel, aryl hydrocarbon receptor agonist, in development a
- News You Can Use: MIPS Hardship Exception Available Nowhttps://practicaldermatology.com/news/news-you-can-use-mips-hardship-exception-available-now/2461702/Physicians may now apply for an Extreme and Uncontrollable Circumstances hardship exception to avoid an up to 9% penalty in the Merit-based Incentive Payment System (MIPS) thanks to advocacy from the American Medical Association and organized medicine about the ongoing impacts of the COVID-19 pub
- Opzelura Helps Beat AD Itchhttps://practicaldermatology.com/news/opzelura-helps-beat-ad-itch/2461690/Opzelura (ruxolitinib) cream 1.5% showed substantial and rapid itch reduction in patients with mild-moderate Atopic Dermatitis (AD). These data were featured in a poster presentation at the Revolutionizing Atopic Dermatitis (RAD) Conference, held from April 29-May 1 in Washing
- Arctiva Eczema Cream Spells Relief for 91% of Patientshttps://practicaldermatology.com/news/study-arctiva-eczema-cream-spells-relief-for-91-of-patients/2461688/Fully 91% of participants reported improvement in eczema irritation using proprietary Arctiva Eczema Cream, a new study shows. Arctiva Eczema Cream features Hydrosurf glycolipid technology—a blend of fermented ingredients with origins from Antarctica. It is combined with 1% C
- The Melanoma Research Alliance, SPOTMYUV Continue Partnership to Promote Sun Safetyhttps://practicaldermatology.com/news/the-melanoma-research-alliance-spotmyuv-continue-partnership-to-promote-sun-safety/2461685/The Melanoma Research Alliance and SPOTMYUV are renewing their partnership to promote sun safety and effective use of sunscreen. The two organizations will co-develop sun safety and skin cancer prevention materials that empower consumers to protect themselves and those they love from UV
- New Class of Immunotherapy Drugs May Fight Melanomahttps://practicaldermatology.com/news/new-class-of-immunotherapy-drugs-may-fight-melanoma/2461682/A new class of immunotherapy shows promising results for fighting melanoma, a new study shows. The study, published in Nature Communications by researchers from King’s College London and Guy’s and St Thomas’ NHS Foundation Trust, investigates whether a n